July 6 Quick Takes: Cellectis CAR T trial halted; plus data readouts from Bellus, ObsEva, Idorsia, and more

Patient death prompts Cellectis trial halt
FDA placed a clinical hold on an allogeneic CAR T therapy trial to treat multiple myeloma from Cellectis S.A. (NASDAQ:CLLS; Euronext:ALCLS) after a patient who received the second-level dose of UCARTCS1A experienced a fatal treatment-emergent adverse event of cardiac arrest. The gene-edited

Read the full 471 word article

How to gain access

Continue reading with a
two-week free trial.